Industry pressures Greek government for dual pricing
This article was originally published in Scrip
The Hellenic Association of Pharmaceutical Companies, SFEE, is behind a move to reintroduce dual pricing in Greece, said its president Dionysios Filiotis of Pharmaserve-Lilly. According to Mr Filiotis, drug prices would be based on the average of 16 Eurozone countries for one set of customers, and a "different" price for the social security funds. Mr Filiotis discussed the scheme as part of a wide-ranging interview with Scrip (see Face to Face scripintelligence.com 23 December 2010).
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.